Clinical Trials Sponsored by Suzhou BlueHorse Therapeutics Co., Ltd.

Total 919 results

Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

Solid Cancer

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Cervical Carcinoma

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours

Solid Tumor

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou Transcenta Therapeutics Co., Ltd.

Not yet recruiting

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

A Study of MSB0254 Injection in Advanced Solid Tumors

Advanced Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Locally Advanced or Metastatic Breast Cancer

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Selected Patients with Advanced Solid Tumors

Breast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid Tumors

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Advanced Solid Tumors

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL201 in Patients with Advanced Solid Tumors

Advanced Solid Tumor

Spain, United States, China, France, Poland, Canada
Suzhou Transcenta Therapeutics Co., Ltd.

Active, not recruiting

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Colorectal Adenocarcinoma | Locally Advanced Solid Tumor | Metastatic Tumor

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
Ocumension Therapeutics (Shanghai) Co., Ltd

Completed

Study of Dexycu in Treating Intraocular Inflammation

Inflammation | Cataract

China
Ocumension Therapeutics (Shanghai) Co., Ltd

Completed

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

Inflammation | Cataract

China
MediLink Therapeutics (Suzhou) Co., Ltd.
BioNTech SE

Recruiting

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, China
MediLink Therapeutics (Suzhou) Co., Ltd.
Hoffmann-La Roche

Recruiting

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

Advanced Solid Tumors

United States, China, Canada, Australia
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Active, not recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Cancer | Advanced Cancer | Gastroesophageal-junction Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Advanced Cancer

China
Ocumension Therapeutics (Suzhou) Co., Ltd
Beijing Children's Hospital

Completed

Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children

Myopia

China
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Recruiting

A Study of DM002 in Patients With Advanced Solid Tumors

Prostatic Neoplasms | Colorectal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Solid Carcinoma

United States, Australia
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Recruiting

A Study of DM001 in Patients With Advanced Solid Tumors

Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Solid Carcinoma

United States, Australia
Suzhou Alphamab Co., Ltd.

Not yet recruiting

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

Hemophilia a and B
Suzhou Alphamab Co., Ltd.

Recruiting

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

Overweight or Obesity

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Completed

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

China, United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation (TRIAD1)

KRAS G12D Mutation

China
Suzhou Kerui Medical Technology Co., Ltd
Suzhou Mingshi Optical Technology Co., Ltd

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

Myopia

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Study of ZG005 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-4375 in Subjects With Solid Tumors

Solid Tumors

China
NGGT (Suzhou) Biotechnology Co., Ltd.

Recruiting

Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects

Phenylketonurias

China
Suzhou Biomissile Pharmaceuticals Co., Ltd.

Recruiting

Study of BM230 in Patients With Advanced Solid Tumors

Solid Tumor

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

Australia, China

Clinical Trials Sponsored by Suzhou BlueHorse Therapeutics Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations